194 related articles for article (PubMed ID: 38253025)
21. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
[TBL] [Abstract][Full Text] [Related]
22. Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy.
Zou Y; Wang Y; Xu S; Liu Y; Yin J; Lovejoy DB; Zheng M; Liang XJ; Park JB; Efremov YM; Ulasov I; Shi B
Adv Mater; 2022 Aug; 34(33):e2203958. PubMed ID: 35738390
[TBL] [Abstract][Full Text] [Related]
23. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
[TBL] [Abstract][Full Text] [Related]
24. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
St-Coeur PD; Poitras JJ; Cuperlovic-Culf M; Touaibia M; Morin P
J Neurooncol; 2015 Oct; 125(1):91-102. PubMed ID: 26311249
[TBL] [Abstract][Full Text] [Related]
25. Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle.
Ren LW; Li W; Zheng XJ; Liu JY; Yang YH; Li S; Zhang S; Fu WQ; Xiao B; Wang JH; Du GH
Acta Pharmacol Sin; 2022 Jan; 43(1):194-208. PubMed ID: 34433903
[TBL] [Abstract][Full Text] [Related]
26. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
27. GC-MS based comparative metabolomic analysis of MCF-7 and MDA-MB-231 cancer cells treated with Tamoxifen and/or Paclitaxel.
Semreen MH; Alniss H; Cacciatore S; El-Awady R; Mousa M; Almehdi AM; El-Huneidi W; Zerbini L; Soares NC
J Proteomics; 2020 Aug; 225():103875. PubMed ID: 32534214
[TBL] [Abstract][Full Text] [Related]
28. Targeted delivery of temozolomide by nanocarriers based on folic acid-hollow TiO
Uribe-Robles M; Ortiz-Islas E; Rodriguez-Perez E; Valverde FF; Lim T; Martinez-Morales AA
Biomater Adv; 2023 Aug; 151():213442. PubMed ID: 37207587
[TBL] [Abstract][Full Text] [Related]
29. Proteomic level changes associated with S3I201 treated U87 glioma cells.
Jain R; Atak A; Yeola A; Srivastava S
J Proteomics; 2017 Jan; 150():341-350. PubMed ID: 27565396
[TBL] [Abstract][Full Text] [Related]
30. Quantitative proteomic analysis of global effect of LLL12 on U87 cell's proteome: An insight into the molecular mechanism of LLL12.
Jain R; Kulkarni P; Dhali S; Rapole S; Srivastava S
J Proteomics; 2015 Jan; 113():127-42. PubMed ID: 25286751
[TBL] [Abstract][Full Text] [Related]
31. Diazepam diminishes temozolomide efficacy in the treatment of U87 glioblastoma cell line.
Drljača J; Popović A; Bulajić D; Stilinović N; Vidičević Novaković S; Sekulić S; Milenković I; Ninković S; Ljubković M; Čapo I
CNS Neurosci Ther; 2022 Sep; 28(9):1447-1457. PubMed ID: 35703405
[TBL] [Abstract][Full Text] [Related]
32. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
[TBL] [Abstract][Full Text] [Related]
33. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Alafate W; Wang M; Zuo J; Wu W; Sun L; Liu C; Xie W; Wang J
Pathol Res Pract; 2019 Nov; 215(11):152617. PubMed ID: 31563286
[TBL] [Abstract][Full Text] [Related]
34. Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis.
Stillger MN; Chen CY; Lai ZW; Li M; Schäfer A; Pagenstecher A; Nimsky C; Bartsch JW; Schilling O
Cancer Cell Int; 2023 Mar; 23(1):49. PubMed ID: 36932402
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanisms of the effect of TGF-β1 on U87 human glioblastoma cells.
Bryukhovetskiy I; Shevchenko V
Oncol Lett; 2016 Aug; 12(2):1581-1590. PubMed ID: 27446475
[TBL] [Abstract][Full Text] [Related]
36. Quantitative proteomics analysis of glioblastoma cell lines after lncRNA HULC silencing.
Ye S; Wu J; Wang Y; Hu Y; Yin T; He J
Sci Rep; 2021 Jun; 11(1):12587. PubMed ID: 34131250
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines.
Balça-Silva J; Matias D; do Carmo A; Girão H; Moura-Neto V; Sarmento-Ribeiro AB; Lopes MC
Biochim Biophys Acta; 2015 Apr; 1850(4):722-32. PubMed ID: 25554223
[TBL] [Abstract][Full Text] [Related]
38. Fibronectin-adherent peripheral blood derived mononuclear cells as Paclitaxel carriers for glioblastoma treatment: An in vitro study.
Schiariti MP; Restelli F; Ferroli P; Benetti A; Berenzi A; Ferri A; Ceserani V; Ciusani E; Cadei M; Finocchiaro G; Pessina A; Parati E; Pallini R; Alessandri G
Cytotherapy; 2017 Jun; 19(6):721-734. PubMed ID: 28434806
[TBL] [Abstract][Full Text] [Related]
39. Quantitative proteomic analysis of GnRH agonist treated GBM cell line LN229 revealed regulatory proteins inhibiting cancer cell proliferation.
Tripathi PH; Akhtar J; Arora J; Saran RK; Mishra N; Polisetty RV; Sirdeshmukh R; Gautam P
BMC Cancer; 2022 Feb; 22(1):133. PubMed ID: 35109816
[TBL] [Abstract][Full Text] [Related]
40. Integrated multi-omics analysis reveals unique signatures of paclitaxel-loaded poly(lactide-co-glycolide) nanoparticles treatment of head and neck cancer cells.
Haider M; Jagal J; Bajbouj K; Sharaf BM; Sahnoon L; Okendo J; Semreen MH; Hamda M; Soares NC
Proteomics; 2023 Aug; 23(16):e2200380. PubMed ID: 37148169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
